Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and ...

At Reuters Pharma USA last month, editor-in-chief Jonah Comstock caught up with John Androsavich, general manager of Ginkgo Datapoints, an AI-driven CRO launched by Ginkgo Bioworks last September. In ...

By leveraging data, digitalisation, and artificial intelligence (AI), the network aims to transform its operations, making them more efficient and responsive to the challenges and opportunities of the ...

Theravia made more than €50 million in revenues in 2024 and has seen its sales rise by an annual rate of around 10% in recent years. For comparison, Norgine has annual revenues of more than €550 ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval.

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the drug rose by more than 160% last year to reach $602 million, placing it on a ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of disease. However, cell and gene therapy (CGT) is ...

Pharma has so far been exempted from Trump's tariff blitz, which imposed a flat rate of 10% on imports from 5th April and much higher levels on countries deemed to have the greatest trade surplus with ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...